Valuation: ProPhase Labs, Inc.

Market Cap 188K 166K 157K 142K 267K 18.06M 271K 1.88M 724K 9.23M 707K 692K 29.6M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 8.72M 7.68M 7.27M 6.57M 12.37M 836M 12.53M 87.01M 33.48M 427M 32.73M 32.02M 1.37B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
92.7%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-13.79%
1 week+900.00%
Current month+934.77%
1 month+492.42%
3 months+35.87%
6 months+38.27%
Current year-72.07%
1 week 0.01
Extreme 0.008
0.14
1 month 0.01
Extreme 0.008
0.14
Current year 0.01
Extreme 0.008
0.47
1 year 0.01
Extreme 0.008
6.66
3 years 0.01
Extreme 0.008
74.8
5 years 0.01
Extreme 0.008
152.5
10 years 0.01
Extreme 0.008
160.4
Manager TitleAgeSince
Chief Executive Officer 67 18/06/2009
Director of Finance/CFO 66 05/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 18/06/2009
Director/Board Member 70 31/05/2009
Director/Board Member 56 19/06/2025
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/25 Free

Chief Executive Officer

500,000 1.2036%
17/02/25 Free

Chief Operating Officer

500,000 1.6737%
14/02/25 Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-13.79%+900.00%-97.27%-99.71% 188K
-1.62%-0.20%+13.66%+22.73% 110B
-1.13%-2.23%+0.13%+73.49% 92.39B
-0.29%+5.76%+156.76%+834.03% 59.58B
-0.39%-4.41%-6.75%+50.03% 28.62B
+0.47%+0.03%+22.30%+91.26% 25.72B
-0.23%+1.36%+7.33%+53.25% 24.99B
-0.79%-0.34%+25.87%+287.86% 20.58B
-1.10%-0.53%-16.49%-6.91% 21.11B
-1.66%-4.47%-3.02%+33.22% 16.95B
Average -2.06%-0.26%+10.25%+133.93% 39.95B
Weighted average by Cap. -0.94%-0.07%+28.89%+176.25%

Financials

2024 2025
Net sales 6.77M 5.96M 5.65M 5.1M 9.61M 649M 9.74M 67.58M 26.01M 332M 25.42M 24.87M 1.06B 4.34M 3.83M 3.63M 3.27M 6.17M 417M 6.25M 43.37M 16.69M 213M 16.32M 15.96M 683M
Net income -53.36M -46.99M -44.52M -40.2M -75.76M -5.12B -76.74M -533M -205M -2.62B -200M -196M -8.39B -14.74M -12.98M -12.3M -11.1M -20.93M -1.41B -21.2M -147M -56.64M -723M -55.36M -54.15M -2.32B
Net Debt 23.9M 21.04M 19.94M 18M 33.92M 2.29B 34.36M 239M 91.79M 1.17B 89.73M 87.77M 3.76B 8.53M 7.51M 7.12M 6.42M 12.11M 818M 12.26M 85.13M 32.76M 418M 32.02M 31.32M 1.34B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
30/09/26 US$0.0121 +20.14% 320,910
29/09/26 US$0.0101 -8.59% 197,081
28/09/26 US$0.0110 -.--% 357,834
25/09/26 US$0.0110 +13.05% 220,196
24/09/26 US$0.009730 -22.16% 217,623

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock